Unibest

Pharmaceutical intermediates

Rimegepant Intermediates

6 pharmaceutical intermediates for Rimegepant. Indication: Migraine.

提交项目All intermediates

About Rimegepant

Originator
Bristol Myers Squibb
Indication
Migraine
Approved Date
02/27/2020
NCE Patent
02/27/2025
DS/DP
03/09/2030

Available intermediates

6 intermediates currently listed for Rimegepant. Request specifications, documentation or a quotation for any item below.

Rimegepant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(5S,6S,9R)-6-(2,3-difluorophenyl)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-aminedihydrochloride1373116-04-1//
7,8-dihydro-5H-cyclohepta[b]pyridine-5,9(6H)-dione39713-40-1//
(R)-9-((triisopropylsilyl)oxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one hydrochloride1190363-45-1//
1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one1373116-06-3//
(6S,9R)-6-(2,3-Difluorophenyl)-6,7,8,9-tetrahydro-9-[[tris(1-methylethyl)silyl]oxy]-5H-cyclohepta[b]pyridin-5-one1190363-46-2//
1-piperidin-4-yl-3H-imidazo[4,5-b]pyridin-2-one,dihydrochloride781649-84-1//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Rimegepant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →